Cover Image

(Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation

Epstein-Barr virus (EBV) primary infection constitutes a serious risk for pediatric transplant recipients, particularly as regards the development of EBV-related post-transplant lymphoproliferative disease (PTLD). Currently, there is no established prophylactic regimen. We investigated the associati...

Full description

Saved in:
Bibliographic Details
Main Authors: Höcker, Britta (Author) , Fickenscher, Helmut (Author) , Schnitzler, Paul (Author) , Feneberg, Reinhard (Author) , Tönshoff, Burkhard (Author)
Format: Article (Journal)
Language:English
Published: 25 April 2012
In: Transplant international
Year: 2012, Volume: 25, Issue: 7, Pages: 723-731
ISSN:1432-2277
DOI:10.1111/j.1432-2277.2012.01485.x
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1111/j.1432-2277.2012.01485.x
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1432-2277.2012.01485.x
Get full text
Author Notes:Britta Höcker, Stephan Böhm, Helmut Fickenscher, Uta Küsters, Paul Schnitzler, Martin Pohl, Ulrike John, Markus J. Kemper, Henry Fehrenbach, Marianne Wigger, Martin Holder, Monika Schröder, Reinhard Feneberg, Sabine Köpf‐Shakib, and Burkhard Tönshoff
Description
Summary:Epstein-Barr virus (EBV) primary infection constitutes a serious risk for pediatric transplant recipients, particularly as regards the development of EBV-related post-transplant lymphoproliferative disease (PTLD). Currently, there is no established prophylactic regimen. We investigated the association between chemoprophylaxis with valganciclovir (VGCV) or ganciclovir (GCV) and the incidence of EBV viremia in EBV-naïve pediatric renal transplant recipients (R−) who had received a graft from an EBV-positive donor (D+) and are therefore at high risk of EBV primary infection. In a prospective, multicenter trial (n = 114), we compared a cohort on chemoprophylaxis (n = 20) with a similar control cohort without chemoprophylaxis (n = 8). Over the 1-year study period, antiviral prophylaxis with VGCV/GCV was associated with a significantly decreased incidence of EBV primary infection: 9/20 patients (45%) in the prophylaxis group experienced an EBV primary infection compared to 8/8 controls (100%) (P < 0.0001). Chemoprophylaxis was associated with a significantly lower EBV viral load (P < 0.001). Type or intensity of immunosuppressive therapy did not influence the occurrence of EBV primary infection or the level/persistence of EBV viral load. Chemoprophylaxis with VGCV/GCV is associated with a reduced incidence of EBV viremia in high-risk pediatric kidney allograft recipients in the first year post-transplant. (ClinicalTrials.gov number: NCT00963248).
Item Description:Gesehen am 13.07.2018
Auch zitiert als: Prophylaxis with (val-)ganciclovir reduces the incidence of Epstein Barr virus primary infection in pediatric renal transplant recipients
Physical Description:Online Resource
ISSN:1432-2277
DOI:10.1111/j.1432-2277.2012.01485.x

Similar Items